PKN:GPWORLEN Spolka Akcyjna Analysis
Data as of 2026-03-11 - not real-time
€76.88
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Technical outlook: Revvity is trading at €76.88, well below its 20‑day SMA of €81.26 and 50‑day SMA of €86.47, indicating a short‑term bearish bias. The 14‑day RSI sits at 36.5, flirting with oversold territory, while the MACD line (‑2.11) is under the signal line (‑1.87) with a negative histogram, reinforcing the bearish momentum. Volume is stable but thin, and 30‑day volatility is high at 35.7%, suggesting price swings could be pronounced.
Fundamental outlook: The stock appears significantly overvalued on a price‑to‑earnings basis (PE ≈ 43 vs industry average ≈ 25) and the DCF fair‑value estimate of €59.28 is well below the market price. However, the forward PE of 12.2 signals strong earnings expectations, and revenue is growing at ~6% with healthy gross (≈55%) and operating margins (≈20%). The dividend yield is modest (0.31%) but the payout ratio is low (≈14%), making the dividend sustainable. Debt is high (≈€3.4 bn) with a debt‑to‑equity of 46.9, which adds leverage risk, while cash flow remains positive. Overall, the stock is overvalued in the near term but may offer upside if earnings materialize as forecasted.
Fundamental outlook: The stock appears significantly overvalued on a price‑to‑earnings basis (PE ≈ 43 vs industry average ≈ 25) and the DCF fair‑value estimate of €59.28 is well below the market price. However, the forward PE of 12.2 signals strong earnings expectations, and revenue is growing at ~6% with healthy gross (≈55%) and operating margins (≈20%). The dividend yield is modest (0.31%) but the payout ratio is low (≈14%), making the dividend sustainable. Debt is high (≈€3.4 bn) with a debt‑to‑equity of 46.9, which adds leverage risk, while cash flow remains positive. Overall, the stock is overvalued in the near term but may offer upside if earnings materialize as forecasted.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 5/10
Key Factors
- Price below key moving averages
- Bearish MACD divergence
- Elevated short‑term volatility
Medium Term
1–3 yearsNeutral
Model confidence: 6/10
Key Factors
- Forward PE suggests earnings acceleration
- Persistent overvaluation relative to DCF
- High leverage and modest ROE
Long Term
> 3 yearsPositive
Model confidence: 7/10
Key Factors
- Strong earnings growth expectations
- Sustainable dividend with low payout
- Potential price correction toward fair value
Key Metrics & Analysis
Financial Health
Revenue Growth5.90%
Profit Margin8.45%
P/E Ratio42.9
ROE3.22%
ROA2.22%
Debt/Equity46.87
P/B Ratio1.4
Op. Cash Flow€582.9M
Free Cash Flow€523.3M
Industry P/E25.2
Technical Analysis
TrendNeutral
RSI36.6
Support€76.48
Resistance€87.18
MA 20€81.26
MA 50€86.47
MA 200€81.35
MACDBearish
VolumeStable
Fear & Greed Index76.91
Valuation
Fair Value€59.28
GradeOvervalued
TypeBlend
Dividend Yield0.31%
Risk Assessment
Beta0.78
Volatility35.69%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskMedium
Liquidity RiskHigh
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.